Table 5.
Serum and CSF sPD-L1 levels in gliomas stratified by disease features.
| Serum | CSF | |||||
|---|---|---|---|---|---|---|
| n | sPD-L1 | p | n | sPD-L1 | p | |
| 73 | 0.5594 (0–1.4235) | – | 31 | 1.3202 (0.0925–22.0392) | – | |
|
WHO grade | ||||||
| LGG | 39 | 0.4623 ± 0.2166 | 0.006* | 14 | 0.325 (0.093–13.701) | 0.029* |
| HGG | 34 | 0.6316 ± 0.2899 | 17 | 2.676 (0.199–22.039) | ||
| Pathology | ||||||
| PA | 8 | 0.4029 ± 0.1512 | 0.036* | 3 | 0.099 (0.092–1.32) | 0.032* |
| LGA | 23 | 0.4521 ± 0.2370 | 7 | 1.470 (0.14–13.701) | ||
| AG | 8 | 0.5393 ± 0.3273 | 6 | 4.034 (0.20–22.04) | ||
| ODG | 8 | 0.5509 ± 0.2047 | 4 | 0.259 (0.18–0.39) | ||
| GBM | 26 | 0.6600 ± 0.2782 | 11 | 2.171 (0.23–13.63) | ||
|
Tumor size | ||||||
| ≤80 cm3a | 37 | 0.5710 ± 0.2448 | 0.333 | 14 | 0.454 (0.092–13.634) | 0.010* |
| >80 cm3 | 36 | 0.5104 ± 0.2855 | 17 | 2.581 (0.199–22.039) | ||
| Ki-67 | ||||||
| ≤10%a | 37 | 0.4618 ± 0.2263 | 0.009* | 14 | 0.325 (0.093–13.701) | 0.029* |
| >10% | 36 | 0.6227 ± 0.2809 | 17 | 2.676 (0.199–22.039) | ||
|
IDH-1 type | ||||||
| Mutant | 37 | 0.5509 ± 0.2973 | 0.595 | 18 | 0.823 (0.18–22.039) | 0.042* |
| Wild type | 22 | 0.5918 ± 0.2595 | 8 | 3.172 (0.15–10.36) | ||
|
1p19q status | ||||||
| Codeleted | 12 | 0.5349 ± 0.2341 | 0.672 | 7 | 0.259 (0.14–4.77) | 0.017* |
| Maintained | 47 | 0.5740 ± 0.2949 | 19 | 2.676 (0.23–22.039) | ||
An asterisk (*) indicates a significant difference.
a
The median value in the glioma cohort.
PA, pilocytic astrocytoma; LGA, low-grade astrocytoma; ODG, oligodendroglioma; AG, anaplastic glioma; GBM, glioblastoma; IDH, isocitrate dehydrogenase.